Factor VIII inhibitors in patients with hemophilia A

Acta Haematologica

Volumn 102, Issue 1, 1999, Pages 42-46

  Ören, Hale ^a   Yaprak, Işin ^a   Irken, Gülersu ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Factor VIII; Hemophilia A; Inhibitors

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; NEUTRALIZING ANTIBODY; NORDIATE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; DISEASE SEVERITY; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; PLASMA TRANSFUSION; PRIORITY JOURNAL; SUBSTITUTION THERAPY;

EID: 0344603874     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040966     Document Type: Article

References (39)

1. Shapiro SS, Hultin M: Acquired inhibitors to the blood coagulation factors. Semin Thromb Hemost 1975;1:336-339.
2. Feinstein DI: Inhibitors in hemophilia; in Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE (eds): Hemotology: Basic Principles and Practice, ed 2. New York, Churchill Livingstone, 1995, pp 1686-1691.
3. Bell B, Canty D, Audet M: Hemophilia: An updated review. Pediatr Rev 1995;16:290-298.
4. Kasper CK: Incidence and course of inhibitors among patients with classic hemophilia. Thromb Diath Haemorrh 1973;30:264-267.
5. Biggs R: Complications of treatment; in Biggs R, Mac Farlane RG (eds): Treatment of Hemophilia A and B and von Willebrand's Disease. London, Blackwell, 1978.
6. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS: Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993;328: 453-459.
7. Bray GL, Liu-Maruya S, Courter S, High K, Gomperts E, Recombinate Study Group: Experience with recombinant factor VIII (Recombinate) in previously untreated patients (PUPs) with severe hemophilia A. Blood 80(suppl 1); 1992:229a.
8. De Biasi R, Rocino A, Papa ML. Salerno T, Mastrullo L, De Blasi D: Incidence of factor VIII inhibitor development in hemophilia patients treated with less pure plasma derived concentrates. Thromb Haemost 1994;71:544-547.
9. Aledort L: Inhibitors in hemophilia patients: Current status and management. Am J Hematol 1994;47:208-217.
10. Scharrer l, Neutzling O: Incidence of inhibitors in haemophiliacs. A review of the literature. Blood Coagul Fibrinolysis 1993;4:753-758.
11. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M. Güngör T, Krackhardt B, Kornhuber B: Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992;339:594-598.
12. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L: Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII. Lancet 1993;342:462-464.
13. Bray G, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G III, Lee M, Recombinate Study Group: A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994;83: 2428-2435.
14. Addiego JE, Gomperts E. Liu SL, Bailey P, Courter SG, Lee ML, Neslund GG, Kingdon HS, Griffith MJ: Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-F VIII C immunoaffinity chromatography. Thromb Haemost 1992;67: 19-27.
15. Lusher JM: Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII:C. Ann Hematol 1991;63:138-141.
16. Lusher JM: Factor VIII inhibitors: Etiology, characterization, natural history and management. Ann NY Acad Sci 1987;509:89-102.
17. Schwarzinger I, Pabinger I, Korninger C, Haschke F, Kundi M, Niessner H, Lechner K: Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol 1987;24: 241-245.
18. Verbruggen B, Novakova I, Wessels H, Boezman J, van den Berg M, Mauser-Bunschoten E: The Nijmegen modification of the Bethesda assay for FVIII:C inhibitors: Improved specificity and reliability. Thromb Haemost 1995; 73:247-251.
19. Lusher JM, Warrier I: Hemophilia A. Hematol Oncol Clin North Am 1992;6:1021-1033.
20. Hoyer LW: Why do so many haemophilia A patients develop an inhibitor? Br J Haematol 1995;90:498-501.
21. Kreuz W, Becker S, Lenz E, Martinez-Saguer I, Escuriola-Ettingshausen C, Funk M, Ehrenforth S, Auerswald G, Kornhuber B: Factor VIII inhibitors in patients with hemophilia A: Epidemiology of inhibitor development and induction of immune tolerance for factor VIII. Semin Thromb Hemostas 1995;21:382-389.
22. Sultan Y, French Hemophilia Study Group: Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 1992;67:600-602.
23. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J, Smit C, Strengers PFW, Briet E, Dutch Hemophilia Study Group: A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood 1993;81:2180-2186.
24. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J: A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993;69:115-118.
25. Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, Rosendaal G, Briet E, van den Berg HM: Clinical course of factor VIII inhibitors developed after exposure to a pasteurized Dutch concentrate compared to classic inhibitors in haemophilia A. Thromb Haemost 1994; 71:703-706.
26. Peerlinck K, Arnout J, Di Giambattista M, Gilles JG, Laub R, Jacquemin M, Saint-Remy JMR, Vermylen J: Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77:80-86.
27. Kessler CM, Sachse K: Factor VIII:C inhibitor associated with monoclonal-antibody purified factor VIII concentrate. Lancet 1990;354: 1403-1404.
28. Allard S, Philpott N, Bevan DH: Factor VIII inhibitors. Lancet 1993;342:1109-1110.
29. Colvin BT, Hay CRM, Hill FGH, Preston FE: The incidence of factor VIII inhibitors in the United Kingdom, 1990-93. Br J Haematol 1995;89:908-910.
30. Peerlinck K, Rosendaal FR, Vermylen J: Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 1993;81:3332-3335.
31. Mc Millan CW, Sandor S, Shapiro SS. Whitehurst D, Hoyer LW, Rao AV, Lazerson J, Hemophilia Study Group: The natural history of factor VIII:C inhibitors in patients with hemophilia A: A national cooperative study II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988;71:344-348.
32. Briet E, Rosendaal FR: Inhibitors in hemophilia A: Are some products safer? Semin Hematol 1994;32:11-15.
33. Briet E, Rosendaal FR, Kreuz W, Rasi V, Peerlinck K, Vermylen J, Ljung R, Rocino A, Addiego J, Lorenzo JI, Pabinger I: High titer inhibitors in severe hemophilia A: A meta analysis based on eight long-term follow-up studies concerning inhibitors as associated with crude or intermediate purity factor VIII products. Thromb Haemost 1994;72:162-164.
34. Briet E: Tolerance and intolerance to F VIII: A clinical prospective; in Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC (eds): Inhibitors to Coagulation Factor. New York, Plenum Press, 1995.
35. Shapiro SS, Hultin M: Acquired inhibitors to the blood coagulation factors. Semin Thromb Hemost 1975;1:336-338.
36. Schimpf K, Schwarz HP, Kunschak M: Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thromb Haemost 1995;73:546-548.
37. Rizza CR, Matthews JM: Effect of frequent factor VIII replacement on the level of factor VIII antibodies in haemophiliacs. Br J Haematol 1982;52:13-24.
38. Nilsson IM: Immune tolerance. Semin Hematol 1994;31:44-48.
39. Kessler CM: Factor VIII inhibitors. An algorithmic approach to treatment. Semin Hematol 1994;31:33-36.